Written By | Health News Agencies
Merck's Lipfendra slashes "bad" cholesterol by up to 59% in trials, matches injectable biologics for the first time — and costs about half as much
Search
HEALTH
For nearly a decade, the most powerful cholesterol-lowering drugs on the market have come with a catch: you had to stab yourself with a needle to get them. Not anymore. The FDA has just approved Lipfendra, the first-ever oral PCSK9 inhibitor — a daily pill that goes toe-to-toe with the injectable cholesterol drugs cardiologists have relied on for years, cutting LDL, the so-called "bad" cholesterol, by more than half in clinical trials.
Cardiologists are calling it a landmark. Patients who have spent years dreading a self-injection every few weeks — or who simply refused to start one — now have a pill they can swallow at the kitchen table alongside their morning coffee. And in a health system where cost keeps millions of Americans from filling the prescriptions they actually need, Lipfendra arrives with a list price roughly half that of its injectable predecessors.
"I'm thrilled," Dr. Christopher Cannon, a cardiologist at Brigham and Women's Hospital in Boston, said of the approval — a sentiment echoed across the cardiology world in the weeks since Merck's announcement.
A Drug Class That Finally Goes Oral
PCSK9 inhibitors have been something of a wonder drug class since they first reached the market roughly a decade ago. They work by blocking a protein called PCSK9, which normally interferes with the liver's ability to clear LDL cholesterol from the bloodstream. Block PCSK9, and the liver can pull far more LDL out of circulation — driving cholesterol levels down dramatically, often in patients for whom statins alone aren't enough.
The problem has always been delivery. Existing PCSK9 inhibitors, drugs like Repatha and Praluent, are monoclonal antibodies — large, complex protein molecules that break down in the digestive system if swallowed, meaning they have to be injected, typically every two to four weeks, for the rest of a patient's life. For many patients, especially those already juggling multiple medications or squeamish about needles, that barrier has meant skipped doses, abandoned treatment, or simply never starting the drug that could have protected their heart.
Merck's breakthrough with Lipfendra, known generically as enlicitide, was solving the chemistry problem that had stumped the field for years: how do you shrink a PCSK9-blocking molecule down small enough to survive the stomach and get absorbed through the gut, while keeping it powerful enough to actually work? The company's answer was a "macrocyclic peptide" — a smaller, ring-shaped molecule that functions differently from the bulky antibodies used in injectable versions but still binds to and blocks PCSK9 effectively. That structural innovation is what finally made an oral PCSK9 inhibitor possible, more than a decade after the injectable versions first launched.
The Numbers Behind The Hype
The FDA's approval, announced by Merck on July 16, rests on data from two pivotal Phase 3 trials, part of the company's CORALreef trial program, which together enrolled more than 3,200 patients with hypercholesterolemia who were already on the maximum statin dose they could tolerate.
In the CORALreef Lipids and CORALreef HeFH trials, patients taking Lipfendra saw their LDL cholesterol drop by a placebo-adjusted 56% and 59%, respectively, by week 24 — numbers that put the pill squarely in line with what injectable PCSK9 inhibitors have delivered in their own trials. Beyond LDL, the drug also lowered other cardiovascular risk markers, including non-HDL cholesterol and apolipoprotein B, both of which are increasingly used by cardiologists to gauge a patient's true heart disease risk beyond the traditional cholesterol number alone.
Safety-wise, the drug performed reassuringly close to placebo in the general hypercholesterolemia trial. In the trial focused on patients with heterozygous familial hypercholesterolemia (HeFH) — a genetic condition that causes dangerously high cholesterol from birth — the most common side effects reported more often than placebo were diarrhea (7% of Lipfendra patients versus 2% on placebo) and dizziness (9% versus 4%).
The FDA approved Lipfendra as an adjunct to diet and exercise for adults with hypercholesterolemia, including those with HeFH, taken once daily as a 20 mg tablet.
The Money Question
Cost has always been the silent villain in the PCSK9 inhibitor story. Injectable versions have historically listed at $500 to $600 or more per month, a price tag that, even with insurance negotiations and manufacturer assistance programs, has kept the drugs out of reach for huge numbers of patients who could benefit. By comparison, a generic statin can cost as little as $4 a month — hugely cheaper, but for many high-risk patients, simply not powerful enough on its own.
Lipfendra threads that needle, literally and figuratively. Merck has set its list price at $315 for a 30-day supply — roughly half of what injectable PCSK9 inhibitors have historically charged. That is still a significant jump from a statin, but a meaningful step down from the injectable biologics it's designed to rival, and cardiologists say the price point alone could open the door to far broader use.
"This would make a big difference compared with the cost of injectable PCSK9 inhibitors," said Dr. David Maron, a preventive cardiologist at Stanford University.
Who Stands To Benefit
Merck's ambition for the drug is bigger than just capturing patients already on injectable PCSK9 inhibitors. The company has said it wants prescribing Lipfendra to feel as routine as prescribing a statin — meaning primary care doctors, not just specialist cardiologists, would be comfortable writing the prescription. That matters enormously in a country where the vast majority of high cholesterol is managed by general practitioners, not cardiology specialists, and where referrals to a cardiologist for an injectable biologic can take months.
Heart disease remains the leading cause of death in the United States, and elevated LDL cholesterol is one of its most well-established, modifiable risk factors. Millions of Americans are prescribed statins as a first-line treatment, but a meaningful share don't hit their target cholesterol levels on statins alone, either because the drug isn't potent enough for their particular risk profile or because they can't tolerate the side effects, which can include muscle pain. For those patients, until now, the next step meant a referral, a prior authorization battle with insurance, and a needle. Lipfendra offers a potentially simpler off-ramp.
Patients with familial hypercholesterolemia — the inherited condition that causes dangerously high LDL from a young age and dramatically raises the risk of early heart attacks — stand to benefit especially, since many already require aggressive combination therapy just to get their numbers into a safer range.
Expert Perspective
The cardiology community's reaction has ranged from enthusiastic to cautiously optimistic. Some researchers have flagged that Lipfendra's approval, like many modern drug approvals, relied on surrogate endpoints — meaning the trials measured how much the drug lowered LDL cholesterol and other lipid markers, rather than directly measuring whether patients who took the pill actually had fewer heart attacks or strokes over time. That kind of hard outcomes data typically takes years of additional follow-up trials to generate, and some industry analysts have pointed to it as a data gap worth watching as Lipfendra reaches a broader patient population outside the tightly controlled conditions of a clinical trial.
Still, since LDL reduction has been one of the most consistently validated predictors of reduced cardiovascular risk across decades of cholesterol research, most cardiologists interviewed following the approval expressed confidence that the drug's real-world cardiovascular benefit will track closely with its dramatic effect on LDL numbers, even before dedicated outcomes trials are complete.
What This Means For You
If you or someone in your family has been told your cholesterol is high despite taking a statin, or if you've been offered — and declined — an injectable PCSK9 inhibitor because of the needle or the cost, this is worth bringing up at your next doctor's visit. Lipfendra is expected to reach pharmacies within weeks of its approval, and because it's designed to be prescribed by primary care doctors as well as cardiologists, patients may not need a specialist referral to access it.
It's not a replacement for statins as a first-line treatment, and it's not a magic bullet for anyone who hasn't already tried lifestyle changes and standard cholesterol-lowering therapy. But for the specific population of patients who need more aggressive LDL reduction than a statin alone provides, and who have been unable or unwilling to start an injectable biologic, Lipfendra represents the biggest shift in cholesterol treatment options in years.
As always, insurance coverage and out-of-pocket costs will vary, and patients should ask their doctor and pharmacist about co-pay assistance programs, which Merck is expected to offer given the drug's relatively high list price compared to generic statins.
The Bottom Line
Lipfendra's approval marks the end of a decade-long race to bring PCSK9-blocking power into pill form, and its combination of injectable-level potency with roughly half the injectable price tag could reshape how millions of Americans manage their heart disease risk. Whether it lives up to the excitement in cardiology offices around the country will depend on real-world use in the months and years ahead — but for now, the needle finally has real competition.
